Hone Bio

Executive Summary

Hone Bio is a pre-clinical biotechnology company based in Bristol, UK, founded in 2019, that is developing a novel platform technology for targeted drug delivery. The company's core innovation, NanoPilot, is an antibody-based fusion protein designed to redirect lipid nanoparticles (LNPs) away from the liver and towards specific extrahepatic cell types. This approach aims to unlock the potential of LNP-delivered nucleic acid therapies for a wide range of diseases beyond the liver, including genetic disorders, oncology, and immune-related conditions. The platform addresses a key limitation of current LNP technology, which is primarily liver-tropic, thereby expanding the therapeutic applicability of nucleic acid medicines. Hone Bio is currently in the pre-clinical stage and has not disclosed funding details or valuation. The company's pipeline is early, but its technology has broad applicability and could be platform-licensed to pharmaceutical partners. Looking ahead, Hone Bio's near-term milestones focus on advancing its lead candidate through IND-enabling studies and generating proof-of-concept data in animal models. The company is also expected to seek strategic partnerships to further develop and commercialize the NanoPilot platform. With the growing interest in extrahepatic delivery of nucleic acid therapies, Hone Bio's technology could attract significant attention from larger biopharma companies. However, as a pre-clinical company, the risk remains high, and success depends on robust preclinical validation and ability to secure funding or partnerships. Key upcoming catalysts include the completion of IND-enabling studies, initial in vivo efficacy data, and potential licensing deals.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-Enabling Studies80% success
• Q2 2026Initial Proof-of-Concept Data in Animal Models for Lead Indication70% success
• Q3 2026Strategic Partnership or Licensing Deal for NanoPilot Platform50% success